

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. - 70. (Canceled)

71. (New) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

- (a) a first vial comprising a vinca alkaloid solution;
- (b) a second vial comprising liposomes in solution, wherein the pH of the interior and exterior of said liposomes is acidic;
- (c) a third vial comprising a buffer solution having a pH higher than the pH of the solution of the second vial, such that combining the solutions of the second and third vials results in the pH of the exterior of said liposomes being neutral; and
- (d) instructions for the use of said kit to prepare liposomal compositions useful in the treatment of a neoplasia in a mammal.

72. (New) The kit of claim 71, wherein said liposomes comprise sphingomyelin and cholesterol.

73. (New) The kit of claim 71, wherein said vinca alkaloid is selected from the group consisting of: vincristine, vinoreline, vinblastine and vindesine.

74. (New) The kit of claim 73, wherein said vinca alkaloid is vincristine.

75. (New) The kit of claim 71, wherein said neoplasia is a relapsed lymphoma or leukemia.

76. (New) The kit of claim 71, wherein the buffer solution of the third vial is an alkaline phosphate buffer.

77. (New) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

- (a) a first vial comprising a solution comprising vincristine sulfate;
- (b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol;
- (c) a third vial comprising an alkaline sodium phosphate buffer solution, wherein adding the solution of the third vial to the combined solutions of the first and second vials results in the pH of the exterior of said liposomes being neutral; and
- (d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.

78. (New) The kit of claim 77, wherein said vincristine sulfate is present at a concentration of approximately 1 mg/ml.

79. (New) The kit of claim 77, wherein the pH of the solution in the first vial is 3.5 to 5.5.

80. (New) The kit of claim 77, wherein said first vial further comprises mannitol.

81. (New) The kit of claim 77, wherein the pH of the interior and exterior of said liposome is acidic.

82. (New) The kit of claim 81, wherein the pH of the interior and exterior of said liposome is approximately 4.0.

83. (New) The kit of claim 77, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of 75/25 (mol% sphingomyelin/mol% cholesterol) to 50/50 (mol% sphingomyelin/mol% cholesterol).

84. (New) The kit of claim 83, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of about 55/45 (mol% sphingomyelin/mol% cholesterol).

85. (New) The kit of claim 77, wherein the pH of the alkaline phosphate buffer solution is approximately 9.0.

86. (New) A kit for use in the treatment of a neoplasia in a mammal, said kit comprising:

(a) a first vial comprising a solution comprising vincristine sulfate at a concentration of approximately 1 mg/ml, mannitol at a concentration of approximately 100 mg/ml, wherein said solution has a pH in the range of 3.5 to 5.5;

(b) a second vial comprising a citrate-buffered solution comprising liposomes comprising sphingomyelin and cholesterol in a ratio of 75/25 (mol% sphingomyelin/mol% cholesterol) to 50/50 (mol% sphingomyelin/mol% cholesterol);

(c) a third vial comprising a buffer solution comprising dibasic sodium phosphate heptahydrate at a concentration of approximately 14.2 mg/ml; and

(d) instructions for the use of said kit to prepare a liposomal composition useful in the treatment of a neoplasia in a mammal.